|
|
Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study
F. Poullenot
,
A. Amiot
,
M. Nachury
,
S. Viennot
,
R. Altwegg
,
et al.
Journal of Crohn's and Colitis, 2022, 16 (1), pp.I362-I363
Article dans une revue
hal-03665876v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)
A. Buisson
,
Mathurin Fumery
,
M. Serrero
,
L. Orsat
,
S. Nancey
,
et al.
2020, pp.S337-S338
Autre publication scientifique
hal-03551532v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Comparison of the risk of clinical recurrence after ileocolonic resection for Crohn's Disease for modified Rutgeerts' score i2a and i2b categories: Individual patient data meta-analysis
P. Rivière
,
J. Pekow
,
N. Hammoudi
,
P. Wils
,
P. de Cruz
,
et al.
Journal of Crohn's and Colitis, 2022, 16 (1), pp.I083-I084
Article dans une revue
hal-03665866v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study
F Poullenot
,
A Amiot
,
M Nachury
,
S Viennot
,
R Altwegg
,
et al.
Article dans une revue
hal-03856600v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|